Results 101 to 110 of about 82,161 (336)

Randomized Multicenter Trial of Sirolimus vs. Prednisone as Initial Therapy for Standard Risk Acute GVHD: BMT CTN 1501.

Blood, 2019
Clinical- and biomarker-based tools may identify a lower risk acute graft-versus-host disease (GVHD) population amenable to novel, reduced intensity treatments. Previous data suggest sirolimus may rival standard of care prednisone.
J. Pidala, M. Hamadani, P. Dawson, M. Martens, A. Alousi, M. Jagasia, Y. Efebera, S. Chhabra, I. Pusic, S. Holtan, J. Ferrara, J. Levine, M. Mielcarek, C. Anasetti, J. Antin, J. Bolaños-Meade, Alan Howard, B. Logan, E. Leifer, T. Pritchard, M. Horowitz, M. MacMillan   +21 more
semanticscholar   +1 more source

Long‐Term (5‐Years) Outcomes of Current Drug‐Eluting Stents in Percutaneous Coronary Intervention: A Network Meta‐Analysis of Randomized Controlled Trials

Catheterization and Cardiovascular Interventions, EarlyView.
ABSTRACT Background Various drug‐eluting stents (DES) are currently used for percutaneous coronary intervention (PCI). However, long‐term trials reveal inconsistent results in head‐to‐head comparisons. Aims To conduct a network meta‐analysis of relevant trials to assess the performance of different DES currently used in PCI.
Aman Goyal, Humza Saeed, Sonia Hurjkaliani, Yusra Mashkoor, Abdullah, Gauranga Mahalwar, Ankur Kalra, Grant W. Reed   +7 more
wiley   +1 more source

Immunosuppression Withdrawal in Liver Transplant Recipients on Sirolimus

Hepatology, 2019
As conversion from calcineurin inhibitor to sirolimus (SRL), a mechanistic target of rapamycin inhibitor (mTOR‐I), has been shown to enhance immunoregulatory profiles in liver transplant (LT) recipients (LTRs), mTOR‐I therapy might allow for increased ...
J. Levitsky, B. Burrell, S. Kanaparthi, L. Turka, S. Kurian, A. Sánchez‐Fueyo, J. Lozano, A. Demetris, Andrew Lesniak, A. Kirk, L. Stempora, Guang-Yu Yang, J. Mathew   +12 more
semanticscholar   +1 more source

Perfil dos pacientes submetidos à angioplastia trasluminal coronariana com stents farmacológicos no Instituto de Cardiologia de Santa Catarina. [PDF]

, 2007
Trabalho de Conclusão de Curso - Universidade Federal de Santa Catarina. Curso de Medicina.
Aquino, Vivian Wuerges de
core  

Repurposing metformin for cancer treatment: current clinical studies. [PDF]

, 2016
In recent years, several studies have presented evidence suggesting a potential role for metformin in anti-cancer therapy. Preclinical studies have demonstrated several anticancer molecular mechanisms of metformin including mTOR inhibition, cytotoxic ...
Altman, Jessica K, Arya, Ayush, Carneiro, Benedito, Chae, Young Kwang, Chandra, Sunandana, Giles, Francis, Kalyan, Aparna, Kaplan, Jason, Malecek, Mary-Kate, Platanias, Leonidas, Shin, Daniel Sanghoon   +10 more
core   +1 more source

Predicting OCT2/MATEs‐Mediated Drug Interactions in Healthy Volunteers and Patients with Chronic Kidney Disease: Insights from Extended Clearance Concept, Endogenous Biomarkers, and In Vitro Inhibition Studies (Perspectives from the International Transporter Consortium)

Clinical Pharmacology &Therapeutics, EarlyView.
Organic cation transporter (OCT) 2 and multidrug and toxin extrusion (MATE) transporters play significant roles in the renal secretion of organic cations and drug–drug interactions (DDIs). Recent in vitro studies indicate that the Ki values for OCT2 exhibit substrate dependency and increase in potency with pre‐incubation.
Satoshi Asano, Aleksandra Galetin, Yoshiko Tomita, Kathleen M. Giacomini, Xiaoyan Chu, Xinning Yang, Toshimichi Nakamura, Hiroyuki Kusuhara, Yuichi Sugiyama   +8 more
wiley   +1 more source

Verrucous venous malformation [PDF]

, 2019
Verrucous venous malformation, also known as verrucous hemangioma, is a superficial vascular malformation with a variable degree of hyperkeratosis that is composed of capillaries and veins in the dermis and sometimes subcutaneous tissue. We describe a 53-
Kim, Gene H, Leavens, Joan, Worswick, Scott   +2 more
core  

Identification of novel therapeutic targets in the PI3K/AKT/mTOR pathway in hepatocellular carcinoma using targeted next generation sequencing. [PDF]

, 2014
Understanding genetic aberrations in cancer leads to discovery of new targets for cancer therapies. The genomic landscape of hepatocellular carcinoma (HCC) has not been fully described. Therefore, patients with refractory advanced/metastatic HCC referred
Janku, Filip, Kaseb, Ahmed O, Kurzrock, Razelle, Tsimberidou, Apostolia M, Wolff, Robert A   +4 more
core   +3 more sources

FIGO guideline on liver disease and pregnancy

International Journal of Gynecology &Obstetrics, EarlyView.
Abstract The number of women entering pregnancy with chronic liver disease is rising. Gestational liver disorders affect 3% of the pregnant population. Both can be associated with significant maternal and fetal morbidity and mortality. European guidance has recently been published to inform management.
Melanie Nana, Virna Medina, Cynthia Maxwell, Ciara McCormick, Gloria Taliani, Ulrich Beuers, Deborah Money, Bo Jacobsson, Anil Kapur, Titus Beyuo, Francisco Ruiloba, Graeme Smith, Lina Bergman, Sharleen O'Reilly, Patrick O'Brien, Mark Hanson, Mary Rosser, Claudio Sosa, Sumaiya Adam, Valerie Guinto, Liona Poon, Fionnuala McAuliffe, Catherine Williamson, on behalf of the FIGO Committee on Impact of Pregnancy on Long‐term Health, FIGO Committee on Infections during Pregnancy and the FIGO Division of Maternal and Newborn Health   +24 more
wiley   +1 more source

A liver transplant patient developed renal injury on tacrolimus and experienced worsening renal function and rhabdomyolysis after switching to sirolimus: a case report

BMC Nephrology
Renal impairment and rhabdomyolysis are rare in transplant patients receiving sirolimus. We report the case of a 54-year-old male who underwent liver transplantation and was initially treated with tacrolimus, mycophenolate mofetil, and glucocorticoids ...
Chang Gao, Zhi-Yu Chen, Liang Ma, Shen-Ju Gou   +3 more
doaj   +1 more source